强效的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）直接作用抗病毒药物为2019冠状病毒病（COVID-19）疫苗提供了重要补充。 - Suppr

Suppr

超能文献

Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines.

作者信息

Pelly Stephen, Liotta Dennis

机构信息

Department of Chemistry, Emory University, Atlanta, Georgia 30322, United States.

出版信息

ACS Cent Sci. 2021 Mar 24;7(3):396-399. doi: 10.1021/acscentsci.1c00258. Epub 2021 Mar 3.

DOI:10.1021/acscentsci.1c00258

PMID:33786374

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7945585/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce11/8006161/d2899a62ab93/oc1c00258_0001.jpg

相似文献

Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines.强效的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）直接作用抗病毒药物为2019冠状病毒病（COVID-19）疫苗提供了重要补充。

ACS Cent Sci. 2021 Mar 24;7(3):396-399. doi: 10.1021/acscentsci.1c00258. Epub 2021 Mar 3.

Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.宿主靶向和直接作用抗病毒药物联合抑制人冠状病毒。

Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0170322. doi: 10.1128/aac.01703-22. Epub 2023 Mar 28.

Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.通过作用于补体级联反应来降低 COVID-19 阳性患者的炎症和促血栓形成高反应状态的药理学方法。

Hum Immunol. 2021 Apr;82(4):264-269. doi: 10.1016/j.humimm.2021.01.007. Epub 2021 Jan 20.

DNA Oligonucleotides as Antivirals and Vaccine Constituents against SARS Coronaviruses: A Prospective Tool for Immune System Tuning.DNA 寡核苷酸作为针对 SARS 冠状病毒的抗病毒和疫苗成分：一种用于免疫系统调节的有前途的工具。

Int J Mol Sci. 2023 Jan 13;24(2):1553. doi: 10.3390/ijms24021553.

Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors.将美国食品药品监督管理局（FDA）批准的丙型肝炎病毒直接作用抗病毒药物重新用作潜在的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）蛋白酶抑制剂。

J Mol Struct. 2022 Feb 15;1250:131920. doi: 10.1016/j.molstruc.2021.131920. Epub 2021 Nov 19.

Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).基于结构的设计的直接作用抗病毒药物，利用宝石二甲基金效应，并能有效抑制严重急性呼吸系统综合症冠状病毒-2（SARS-CoV-2）和中东呼吸系统综合症冠状病毒（MERS-CoV）的 3CL 蛋白酶。

Eur J Med Chem. 2023 Jun 5;254:115376. doi: 10.1016/j.ejmech.2023.115376. Epub 2023 Apr 15.

Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.用于筛选针对 SARS-CoV-2 的中和抗体和抗病毒药物的快速体外检测方法。

J Virol Methods. 2021 Jan;287:113995. doi: 10.1016/j.jviromet.2020.113995. Epub 2020 Oct 14.

Current and Future Direct-Acting Antivirals Against COVID-19.当前及未来用于对抗新冠病毒的直接作用抗病毒药物。

Front Microbiol. 2020 Nov 12;11:587944. doi: 10.3389/fmicb.2020.587944. eCollection 2020.

The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters.美国食品和药物管理局批准的药物考比司他与瑞德西韦协同抑制 SARS-CoV-2 复制，降低叙利亚仓鼠的病毒滴度和疾病进展。

mBio. 2022 Apr 26;13(2):e0370521. doi: 10.1128/mbio.03705-21. Epub 2022 Mar 1.

Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.贝曲沙班与双嘧达莫联用在体外对 SARS-CoV-2 表现出协同的抗病毒活性：COVID-19 宿主靶向抗病毒治疗策略的理由。

Antiviral Res. 2022 Oct;206:105403. doi: 10.1016/j.antiviral.2022.105403. Epub 2022 Aug 28.

引用本文的文献

Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.探索奈玛特韦的 P1 和 P4 修饰：SARS-CoV-2 Mpro 抑制剂的设计、合成、生物学评价和 X 射线结构研究。

Eur J Med Chem. 2024 Mar 5;267:116132. doi: 10.1016/j.ejmech.2024.116132. Epub 2024 Feb 1.

Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2.主蛋白酶和类木瓜蛋白酶作为新型冠状病毒SARS-CoV-2药物治疗的潜在靶点。

RSC Adv. 2023 Dec 6;13(50):35500-35524. doi: 10.1039/d3ra06479d. eCollection 2023 Nov 30.

Computer-aided drug design for virtual-screening and active-predicting of main protease (M) inhibitors against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）主要蛋白酶（M）抑制剂的虚拟筛选和活性预测的计算机辅助药物设计

Front Pharmacol. 2023 Nov 7;14:1288363. doi: 10.3389/fphar.2023.1288363. eCollection 2023.

Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir "S-217622": A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species.新型研究性抗SARS-CoV-2药物恩昔瑞韦（S-217622）：在冠状病毒治疗前线极具潜力的通用广谱抗病毒药物

ACS Omega. 2023 Jan 30;8(6):5234-5246. doi: 10.1021/acsomega.2c03881. eCollection 2023 Feb 14.

Predicting and Anti-SARS-CoV-2 Activities of Antivirals by Intracellular Bioavailability and Biochemical Activity.通过细胞内生物利用度和生化活性预测抗病毒药物及抗SARS-CoV-2活性

ACS Omega. 2022 Nov 29;7(49):45023-45035. doi: 10.1021/acsomega.2c05376. eCollection 2022 Dec 13.

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.S-217622 的发现：一种非共价的口服 SARS-CoV-2 3CL 蛋白酶抑制剂临床候选药物，用于治疗 COVID-19。

J Med Chem. 2022 May 12;65(9):6499-6512. doi: 10.1021/acs.jmedchem.2c00117. Epub 2022 Mar 30.

J Mol Struct. 2022 Feb 15;1250:131920. doi: 10.1016/j.molstruc.2021.131920. Epub 2021 Nov 19.

Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery.共结晶与结构测定：抗SARS-CoV-2药物发现的有效方向。

Comput Struct Biotechnol J. 2021;19:4684-4701. doi: 10.1016/j.csbj.2021.08.029. Epub 2021 Aug 19.

Time to 'Mind the Gap' in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2.新型小分子直接作用抗病毒药物治疗 SARS-CoV-2 的药物研发需重视“差距”

Curr Opin Virol. 2021 Oct;50:1-7. doi: 10.1016/j.coviro.2021.06.008. Epub 2021 Jun 29.

本文引用的文献

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations.基于自由能微扰计算指导的药物吡仑帕奈分子塑造得到的新型严重急性呼吸综合征冠状病毒2主蛋白酶非共价抑制剂

ACS Cent Sci. 2021 Mar 24;7(3):467-475. doi: 10.1021/acscentsci.1c00039. Epub 2021 Feb 22.

COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies.COVID-19 疫苗：管道疫苗的最新更新、设计和开发策略。

Eur J Pharmacol. 2021 Feb 5;892:173751. doi: 10.1016/j.ejphar.2020.173751. Epub 2020 Nov 25.

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.酮基共价抑制剂冠状病毒 3CL 蛋白酶的发现，为 COVID-19 的潜在治疗提供了可能。

J Med Chem. 2020 Nov 12;63(21):12725-12747. doi: 10.1021/acs.jmedchem.0c01063. Epub 2020 Oct 15.

The race for coronavirus vaccines: a graphical guide.新冠疫苗竞赛：图解指南

Nature. 2020 Apr;580(7805):576-577. doi: 10.1038/d41586-020-01221-y.

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.SARS-CoV-2 主蛋白酶的晶体结构为设计改良的 α-酮酰胺抑制剂提供了基础。

Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验